Navigating Insurance Barriers in IgG4-RD Care: Insights from the Alliance for Patient Access and the IgG4-RD Community

Navigating the healthcare system can be a daunting task, especially for those living with rare conditions like IgG4-related disease (IgG4-RD). The complexities of insurance often make access to appropriate and timely treatments challenging, leading to frustration for both patients and their healthcare providers. We explore here some of the most common insurance barriers faced by the IgG4-RD community and share strategies for overcoming them.

To offer a deeper understanding, we performed a survey through our Online Community of 62 people living with IgG4-RD to gather their perspectives. We also held discussions with Ryan Crump and Casey McPherson from the Alliance for Patient Access (AfPA). The AfPA is a national network of physicians and healthcare providers dedicated to ensuring patient access to approved therapies and appropriate clinical care. The organization advocates for healthcare policies that prioritize patient-centered care, working to remove barriers to access and promoting informed, shared decision-making between patients and their healthcare providers. AfPA also focuses on educating policymakers, the media, and the public about the importance of patient access to care and treatment.

For those living with IgG4-RD, the path to diagnosis is often long and arduous. Even after receiving a diagnosis, patients frequently encounter additional challenges, particularly with health insurance.

According to the AfPA: “Insurers often make it difficult to access medication, even for serious conditions like IgG4-RD.”

One significant hurdle is prior authorization, a process that requires insurance companies to pre-approve treatments before administration – even if those therapies have already received regulatory approval by the U.S. Food & Drug Administration.

AfPA explains that “patients frequently encounter barriers such as prior authorization,” which can delay care from days to even months – a dangerous and unacceptable delay for those who need treatment.

The survey of our IgG4ward! membership indicated that 39% of respondents had experienced denial by their insurance of coverage or payment for a recommended IgG4-RD treatment.

This statistic underscores the real-world impact of such barriers, which can delay crucial care and affect outcomes adversely.

Another challenge explained by the AfPA, is step therapy. This requires patients to try “insurer-preferred medications.” These medications, generally less expensive and often of unproven effectiveness, are often a necessary roadblock that patients must negotiate before access is granted to the treatments that doctors have recommended, and which have been demonstrated to be effective in clinical trials. AfPA emphasizes that “both of these insurance practices can lead to delayed care, impacting patient outcomes.”

Other key insights from our survey were as follows:

• Access to Care: 53% of respondents reported finding it somewhat difficult to very difficult to access care for their IgG4-RD. Only about 1 in 5 respondents (22%) found it very easy to easy to access the care they needed.

• Challenges: The biggest challenges faced by respondents include finding a knowledgeable/experienced IgG4-RD specialist (69%), difficulty coordinating care between multiple doctors (66%) and long wait times to see a specialist (53%). A portion of respondents also struggled with lack of insurance coverage or high out-of-pocket costs (21%).

• Forced medication changes: 10% of respondents had to change medications due to lack of insurance coverage or high out-of-pocket costs. Of those affected in this way, 29% indicated that the medication change had impacted their overall health adversely.

These insights paint a clear picture of the difficulties that people living with IgG4-RD face in securing timely and effective care, reinforcing the need for continued advocacy and support within the community.

AfPA emphasizes the importance of patients taking an active role in their care. “Shared decision-making is central to patient-centered care,” AfPA notes, adding that “patients who engage in this process are better equipped to advocate for themselves.” By being informed and proactive, patients can help ensure they have access to the full range of treatment options for IgG4-RD. AfPA also encourages patients to report any insurance barriers they encounter so that the organization can assist in overcoming these obstacles.

A significant advance for the IgG4-RD community is the introduction of an ICD-10 code specifically for IgG4-RD. The ICD-10 code for IgG4-RD is 89.84. “An ICD-10 code for IgG4-RD allows healthcare providers to specifically include IgG4-RD as a diagnosis,” AfPA explains. The availability of this code is expected to facilitate quicker and smoother access to new treatments as they become available. Moreover, the clarity provided by the ICD-10 code will likely reduce roadblocks patients face when seeking insurance approvals for IgG4-RD treatments.

AfPA offers a variety of resources to help IgG4-RD patients navigate insurance challenges. These include educational materials for patients, clinicians, and policymakers, as well as a clinician-authored white paper on IgG4-RD and access barriers. AfPA can also connect patients with specific resources tailored to overcoming insurance-related issues.

Our survey respondents indicated that the most helpful resources for overcoming barriers would be:

• More IgG4-RD specialist providers in their area (76%),

• Improved coordination between doctors (62%)

• Better insurance coverage and lower of out-of-pocket costs (36%).

These findings highlight the critical need for targeted resources and support within the IgG4-RD community, and help the Foundation focus its efforts.

Staying informed about changes in insurance policies is crucial for IgG4-RD patients. AfPA notes “the online community that IgG4ward! hosts is a fantastic resource to stay plugged into the latest news relevant to IgG4-RD.” In addition, AfPA’s blog, Health Policy Today, frequently provides updates on topics relevant to IgG4-RD, making it another valuable resource for patients and caregivers.

Insurance barriers are a significant challenge for many living with IgG4-RD, but by staying informed, advocating for oneself and utilizing available resources, patients can navigate these obstacles more effectively. The AfPA continues to work towards making treatments more accessible for all IgG4-RD patients. The insights from both experts and the IgG4-RD community offer a roadmap for overcoming these challenges.

We look forward to learning more from the AfPA at The JAM in November. At The JAM, Mr. Crump and Mr. McPherson will host two breakout sessions, sharing their insights on overcoming barriers to care.